NAGE
Price
$6.53
Change
+$0.13 (+2.03%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
532.31M
97 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$11.45
Change
+$0.20 (+1.78%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
2.49B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAGE vs OCUL

Header iconNAGE vs OCUL Comparison
Open Charts NAGE vs OCULBanner chart's image
Niagen Bioscience
Price$6.53
Change+$0.13 (+2.03%)
Volume$35.1K
Capitalization532.31M
Ocular Therapeutix
Price$11.45
Change+$0.20 (+1.78%)
Volume$97.05K
Capitalization2.49B
NAGE vs OCUL Comparison Chart in %
NAGE
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NAGE vs. OCUL commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAGE is a StrongBuy and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (NAGE: $6.39 vs. OCUL: $11.25)
Brand notoriety: NAGE and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAGE: 37% vs. OCUL: 38%
Market capitalization -- NAGE: $532.31M vs. OCUL: $2.49B
NAGE [@Biotechnology] is valued at $532.31M. OCUL’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAGE’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • NAGE’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than NAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAGE’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 6 bullish TA indicator(s).

  • NAGE’s TA Score: 4 bullish, 3 bearish.
  • OCUL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than NAGE.

Price Growth

NAGE (@Biotechnology) experienced а -9.16% price change this week, while OCUL (@Biotechnology) price change was -7.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

NAGE is expected to report earnings on Mar 11, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.5B) has a higher market cap than NAGE($532M). OCUL YTD gains are higher at: 31.733 vs. NAGE (20.547). NAGE has higher annual earnings (EBITDA): 18.1M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. NAGE (60.3M). NAGE has less debt than OCUL: NAGE (3.29M) vs OCUL (76.9M). NAGE has higher revenues than OCUL: NAGE (116M) vs OCUL (56.7M).
NAGEOCULNAGE / OCUL
Capitalization532M2.5B21%
EBITDA18.1M-200.5M-9%
Gain YTD20.54731.73365%
P/E Ratio27.79N/A-
Revenue116M56.7M205%
Total Cash60.3M391M15%
Total Debt3.29M76.9M4%
FUNDAMENTALS RATINGS
NAGE vs OCUL: Fundamental Ratings
NAGE
OCUL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
8792
SMR RATING
1..100
2597
PRICE GROWTH RATING
1..100
8444
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5024

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as NAGE (77) in the Chemicals Specialty industry. This means that OCUL’s stock grew similarly to NAGE’s over the last 12 months.

NAGE's Profit vs Risk Rating (87) in the Chemicals Specialty industry is in the same range as OCUL (92) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew similarly to OCUL’s over the last 12 months.

NAGE's SMR Rating (25) in the Chemicals Specialty industry is significantly better than the same rating for OCUL (97) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew significantly faster than OCUL’s over the last 12 months.

OCUL's Price Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for NAGE (84) in the Chemicals Specialty industry. This means that OCUL’s stock grew somewhat faster than NAGE’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NAGE (100) in the Chemicals Specialty industry. This means that OCUL’s stock grew similarly to NAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NAGEOCUL
RSI
ODDS (%)
Bullish Trend 6 days ago
73%
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
84%
Bearish Trend 6 days ago
85%
Momentum
ODDS (%)
Bearish Trend 6 days ago
87%
Bullish Trend 6 days ago
79%
MACD
ODDS (%)
N/A
Bullish Trend 6 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
83%
Bullish Trend 6 days ago
85%
Advances
ODDS (%)
Bullish Trend 22 days ago
79%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 28 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NAGE
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUXFX32.90N/A
N/A
Auxier Focus Inv
IHGIX37.85N/A
N/A
Hartford Dividend and Growth A
SLVRX39.46N/A
N/A
Columbia Select Large Cap Value R
BGVIX37.15N/A
N/A
Brandes Global Equity I
DGFCX30.82N/A
N/A
Davis Global C

NAGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAGE has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAGE jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAGE
1D Price
Change %
NAGE100%
-4.12%
AXON - NAGE
43%
Loosely correlated
+0.91%
AMRN - NAGE
35%
Loosely correlated
-0.38%
CYTK - NAGE
35%
Loosely correlated
-3.79%
ARRY - NAGE
34%
Loosely correlated
-0.13%
OCUL - NAGE
34%
Loosely correlated
-3.93%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-3.93%
IDYA - OCUL
55%
Loosely correlated
-1.75%
EYPT - OCUL
54%
Loosely correlated
-4.00%
ERAS - OCUL
54%
Loosely correlated
-3.50%
RVMD - OCUL
53%
Loosely correlated
-0.65%
DNLI - OCUL
52%
Loosely correlated
-1.71%
More